Citation Report
List of articles citing

Progress in the development of human parainfluenza virus vaccines

DOI: 10.1586/ers.11.32
Expert Review of Respiratory Medicine, 2011, 5, 515-26.

#	Paper	IF	Citations
88	Pathogenesis of acute respiratory illness caused by human parainfluenza viruses. *Current Opinion in Virology*, **2012**, 2, 294-9	7.5	49
87	Exposing the flexibility of human parainfluenza virus hemagglutinin-neuraminidase. *Journal of the American Chemical Society*, **2012**, 134, 18447-52	16.4	14
86	Pulmonary vaccine delivery: a realistic approach?. *Journal of Aerosol Medicine and Pulmonary Drug Delivery*, **2012**, 25, 249-60	3.8	41
85	Recent developments with live-attenuated recombinant paramyxovirus vaccines. *Reviews in Medical Virology*, **2013**, 23, 15-34	11.7	19
84	Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children. *Vaccine*, **2013**, 31, 5706-12	4.1	34
83	A replication-incompetent influenza virus bearing the HN glycoprotein of human parainfluenza virus as a bivalent vaccine. *Vaccine*, **2013**, 31, 6239-46	4.1	8
82	Influence of antigen insertion site and vector dose on immunogenicity and protective capacity in Sendai virus-based human parainfluenza virus type 3 vaccines. *Journal of Virology*, **2013**, 87, 5959-69	6.6	7
81	Respiratory virus infections in hospitalized children and adults in Lao PDR. *Influenza and Other Respiratory Viruses*, **2013**, 7, 1070-8	5.6	34
80	Alix serves as an adaptor that allows human parainfluenza virus type 1 to interact with the host cell ESCRT system. *PLoS ONE*, **2013**, 8, e59462	3.7	9
79	Development of oligomannose-coated liposome-based nasal vaccine against human parainfluenza virus type 3. *Frontiers in Microbiology*, **2013**, 4, 346	5.7	21
78	Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection. *Journal of Virology*, **2014**, 88, 4237-50	6.6	18
77	Paramyxoviruses: Parainfluenza Viruses. **2014**, 579-600		4
76	New Epidemiological and Clinical Signatures of 18 Pathogens from Respiratory Tract Infections Based on a 5-Year Study. *PLoS ONE*, **2015**, 10, e0138684	3.7	21
75	Relationships among dissemination of primary parainfluenza virus infection in the respiratory tract, mucosal and peripheral immune responses, and protection from reinfection: a noninvasive bioluminescence-imaging study. *Journal of Virology*, **2015**, 89, 3568-83	6.6	10
74	Evaluation of a Live-Attenuated Human Parainfluenza Type 1 Vaccine in Adults and Children. *Journal of the Pediatric Infectious Diseases Society*, **2015**, 4, e143-6	4.8	17
73	Parainfluenza Virus Infection Among Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Children and Adults Hospitalized for Severe Acute Respiratory Illness in South Africa, 2009-2014. *Open Forum Infectious Diseases*, **2015**, 2, ofv139	1	6
72	Cross-immunity between strains explains the dynamical pattern of paramyxoviruses. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 13396-400	11.5	33

71	Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine. *Journal of Virology*, **2015**, 89, 10319-32	6.6	11
70	Respiratory Syncytial Virus, Human Metapneumovirus, and Parainfluenza Viruses. **2016**, 873-902		0
69	A dual drug regimen synergistically blocks human parainfluenza virus infection. *Scientific Reports*, **2016**, 6, 24138	4.9	12
68	Parainfluenza Virus Infection. *Seminars in Respiratory and Critical Care Medicine*, **2016**, 37, 538-54	3.9	77
67	A molecular epidemiological study of human parainfluenza virus type 3 at a tertiary university hospital during 2013-2015 in Catalonia, Spain. *Diagnostic Microbiology and Infectious Disease*, **2016**, 86, 153-9	2.9	15
66	Estimates of Parainfluenza Virus-Associated Hospitalizations and Cost Among Children Aged Less Than 5 Years in the United States, 1998-2010. *Journal of the Pediatric Infectious Diseases Society*, **2016**, 5, 7-13	4.8	36
65	Phylogenetic and molecular analyses of human parainfluenza type 3 virus in Buenos Aires, Argentina, between 2009 and 2013: The emergence of new genetic lineages. *Infection, Genetics and Evolution*, **2016**, 39, 85-91	4.5	10
64	Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses. *Expert Review of Vaccines*, **2016**, 15, 189-200	5.2	22
63	Epidemiology of parainfluenza infection in England and Wales, 1998-2013: any evidence of change?. *Epidemiology and Infection*, **2017**, 145, 1210-1220	4.3	12
62	Parainfluenza Virus in the Hospitalized Adult. *Clinical Infectious Diseases*, **2017**, 65, 1570-1576	11.6	21
61	Vaccines in the Prevention of Viral Pneumonia. *Clinics in Chest Medicine*, **2017**, 38, 155-169	5.3	7
60	Advances in Vaccines to Prevent Viral Respiratory Illnesses in Children. *Paediatric Drugs*, **2017**, 19, 523-531	4.2	7
59	Vaccination with a human parainfluenza virus type 3 chimeric FHN glycoprotein formulated with a combination adjuvant induces protective immunity. *Vaccine*, **2017**, 35, 7139-7146	4.1	7
58	Record linkage study of the pathogen-specific burden of respiratory viruses in children. *Influenza and Other Respiratory Viruses*, **2017**, 11, 502-510	5.6	13
57	The potential influence of human parainfluenza viruses detected during hospitalization among critically ill patients in Kuwait, 2013-2015. *Virology Journal*, **2017**, 14, 19	6.1	3
56	Noninfluenza Respiratory Viruses. **2017**, 1472-1482.e5		2
55	Structural and functional specificity of Influenza virus haemagglutinin and paramyxovirus fusion protein anchoring peptides. *Virus Research*, **2017**, 227, 183-199	6.4	5
54	Functional analysis of amino acids at stalk/head interface of human parainfluenza virus type 3 hemagglutinin-neuraminidase protein in the membrane fusion process. *Virus Genes*, **2018**, 54, 333-342	2.3	0

53	Evaluation of a Live Attenuated Human Metapneumovirus Vaccine in Adults and Children. *Journal of the Pediatric Infectious Diseases Society*, **2018**, 7, 86-89	4.8	14
52	Clinical and epidemiological characteristics of human parainfluenza virus infections of children in southern Taiwan. *Journal of Microbiology, Immunology and Infection*, **2018**, 51, 749-755	8.5	7
51	Inflammasome Antagonism by Human Parainfluenza Virus Type 3 C Protein. *Journal of Virology*, **2018**, 92,	6.6	18
50	Exploring the impact of inoculum dose on host immunity and morbidity to inform model-based vaccine design. *PLoS Computational Biology*, **2018**, 14, e1006505	5	20
49	A Novel Squirrel Respirovirus with Putative Zoonotic Potential. *Viruses*, **2018**, 10,	6.2	8
48	Seroprevalence of Human Parainfluenza Virus Types 1-4 Among Healthy Children Under 5 Years of Age in Korea. *Viral Immunology*, **2018**, 31, 352-357	1.7	3
47	Transcriptome analysis identifies the potential roles of long non-coding RNAs during parainfluenza virus infection. *FEBS Letters*, **2018**, 592, 2444-2457	3.8	2
46	A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3. *Antiviral Research*, **2018**, 158, 78-87	10.8	6
45	Genotype replacement of the human parainfluenza virus type 2 in Croatia between 2011 and 2017 - the role of neutralising antibodies. *Epidemiology and Infection*, **2018**, 146, 1372-1383	4.3	1
44	An Outbreak of Human Parainfluenza Virus 3 (Phylogenetic Subcluster C5) Infection among Adults at a Residential Care Facility for the Disabled in Croatia, 2018. *Intervirology*, **2019**, 62, 174-181	2.5	4
43	Targeting Human Parainfluenza Virus Type-1 Haemagglutinin-Neuraminidase with Mechanism-Based Inhibitors. *Viruses*, **2019**, 11,	6.2	3
42	Will Attention by Vaccine Developers to the Host's Nuclear Hormone Levels and Immunocompetence Improve Vaccine Success?. *Vaccines*, **2019**, 7,	5.3	9
41	New antiviral approaches for human parainfluenza: Inhibiting the haemagglutinin-neuraminidase. *Antiviral Research*, **2019**, 167, 89-97	10.8	12
40	Maternal vaccination with a novel chimeric glycoprotein formulated with a polymer-based adjuvant provides protection from human parainfluenza virus type 3 in newborn lambs. *Antiviral Research*, **2019**, 162, 54-60	10.8	4
39	T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders. *International Review of Cell and Molecular Biology*, **2019**, 342, 175-263	6	3
38	Human parainfluenza virus circulation, United States, 2011-2019. *Journal of Clinical Virology*, **2020**, 124, 104261	14.5	13
37	Characteristics of human parainfluenza virus type 4 infection in hospitalized children in Korea. *Pediatrics International*, **2020**, 62, 52-58	1.2	4
36	A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV. *Journal of Virology*, **2020**, 95,	6.6	3

35	Innate and adaptive immune responses in respiratory virus infection: implications for the clinic. *Expert Review of Respiratory Medicine*, **2020**, 14, 1141-1147	3.8	5
34	INFECTIONS IN PREGNANCY WITH COVID-19 AND OTHER RESPIRATORY RNA VIRUS DISEASES ARE RARELY, IF EVER, TRANSMITTED TO THE FETUS: EXPERIENCES WITH CORONAVIRUSES, HPIV, hMPV RSV, AND INFLUENZA. *Archives of Pathology and Laboratory Medicine*, **2020**,	5	54
33	Hijacking the Fusion Complex of Human Parainfluenza Virus as an Antiviral Strategy. *MBio*, **2020**, 11,	7.8	7
32	Effects of climatic factors on human parainfluenza 1, 2, and 3 infections in Cheonan, Republic of Korea. *Environmental Science and Pollution Research*, **2021**, 28, 10018-10026	5.1	2
31	Advances in the development of entry inhibitors for sialic-acid-targeting viruses. *Drug Discovery Today*, **2021**, 26, 122-137	8.8	9
30	Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults. *Human Vaccines and Immunotherapeutics*, **2021**, 17, 554-559	4.4	7
29	Engineering protease-resistant peptides to inhibit human parainfluenza viral respiratory infection.		
28	Engineering Protease-Resistant Peptides to Inhibit Human Parainfluenza Viral Respiratory Infection. *Journal of the American Chemical Society*, **2021**, 143, 5958-5966	16.4	4
27	Clinical features of parainfluenza infections among young children hospitalized for acute respiratory illness in Amman, Jordan. *BMC Infectious Diseases*, **2021**, 21, 323	4	2
26	Evaluation of Microalgae Antiviral Activity and Their Bioactive Compounds. *Antibiotics*, **2021**, 10,	4.9	6
25	Virological Surveillance and Molecular Characterization of Human Parainfluenzavirus Infection in Children with Acute Respiratory Illness: Germany, 2015-2019. *Microorganisms*, **2021**, 9,	4.9	0
24	Global burden of acute lower respiratory infection associated with human parainfluenza virus in children younger than 5 years for 2018: a systematic review and meta-analysis. *The Lancet Global Health*, **2021**, 9, e1077-e1087	13.6	4
23	Curcumin Inhibits Replication of Human Parainfluenza Virus Type 3 by Affecting Viral Inclusion Body Formation. *BioMed Research International*, **2021**, 2021, 1807293	3	3
22	Pathogenesis of a novel porcine parainfluenza virus type 1 isolate in conventional and colostrum deprived/caesarean derived pigs. *Virology*, **2021**, 563, 88-97	3.6	3
21	Epidemiology and seasonality of human parainfluenza serotypes 1-3 in Australian children. *Influenza and Other Respiratory Viruses*, **2021**, 15, 661-669	5.6	2
20	Human Acute and Chronic Viruses: Host-Pathogen Interactions and Therapeutics. **2020**, 1-120		1
19	Genetic analysis of human parainfluenza virus type 3 obtained in Croatia, 2011-2015. *Journal of Medical Microbiology*, **2017**, 66, 502-510	3.2	11
18	Parainfluenza virus entry at the onset of infection. *Advances in Virus Research*, **2021**, 111, 1-29	10.7	1

17	Human parainfluenza virus evolution during lung infection of immunocompromised individuals promotes viral persistence. *Journal of Clinical Investigation*, **2021**, 131,	15.9	2
16	Metabolic Modifications by Common Respiratory Viruses and Their Potential as New Antiviral Targets. *Viruses*, **2021**, 13,	6.2	3
15	Parainfluenza Virus. **2014**, 87-93		
14	Parainfluenza Viruses. **2015**, 1937-1941.e2		1
13	Exploring the impact of inoculum dose on host immunity and morbidity to inform model-based vaccine design.		0
12	Climate variability and seasonal patterns of paediatric parainfluenza infections in the tropics: An ecological study in Singapore. *International Journal of Hygiene and Environmental Health*, **2022**, 239, 113864	6.9	1
11	The Transmembrane Protease TMPRSS2 as a Therapeutic Target for COVID-19 Treatment.. *International Journal of Molecular Sciences*, **2022**, 23,	6.3	5
10	Human Parainfluenza 2 & 4: clinical and genetic epidemiology in the UK, 2013-2017, reveals distinct disease features and co-circulating genomic subtypes.		
9	Human Defense Mechanisms Against Viruses Causing Acute Respiratory Infections. **2021**, 88-103		
8	SeV C Protein Plays a Role in Restricting Macrophage Phagocytosis by Limiting the Generation of Intracellular Double-Stranded RNA.. *Frontiers in Microbiology*, **2022**, 13, 780534	5.7	
7	Modeling Infection and Tropism of Human Parainfluenza Virus Type 3 in Ferrets.. *MBio*, **2022**, e0383121	7.8	0
6	Prevalence of respiratory viruses in community-acquired pneumonia in children: a systematic review and meta-analysis. *The Lancet Child and Adolescent Health*, **2022**,	14.5	1
5	The Impact of COVID-19 on Reproduction: Contraceptive Access, Pregnancy Rates, Pregnancy Delay, and the Role of Vaccination. *F&S Reviews*, **2022**,	0.5	0
4	Human parainfluenza 2 & 4: Clinical and genetic epidemiology in the UK, 2013–2017, reveals distinct disease features and co-circulating genomic subtypes. *Influenza and Other Respiratory Viruses*,	5.6	
3	Paramyxoviruses: Parainfluenza Viruses. **2022**, 1-50		
2	Intracellular immunoglobulin A (icIgA) in protective immunity and vaccines.		0
1	Antiviral Potential of Curcumins: Ethnopharmacology, Chemistry, and Clinical Studies Focusing on Mechanism of Action and Future Perspectives. **2023**, 1-36		0